Sakar Healthcare Profit Rises 149.12% to 11.31 Crore Rupees in Second Quarter
Key Facts
Sakar Healthcare reported unaudited results for the quarter ended September 30, 2026, with net profit of 11.31 crore rupees, up 149.12% year on year. The published results showed net profit rising from 4.54 crore rupees in the corresponding period of the previous financial year. The surge coincided with operating revenue growth to 87.41 crore rupees from 57.56 crore a year earlier, an increase of 51.9%. The figures reflect simultaneous expansion in revenue and profitability in the second quarter of financial year 2027. EBITDA also rose to 24.34 crore rupees, up 114% year on year.
Net profit margin was 13% in the quarter, according to the published results. Net profit rose from 10.28 crore rupees in the first quarter of financial year 2027 to 11.31 crore in the second quarter. Revenue also increased from 72.97 crore rupees in the previous quarter to 87.42 crore in the quarter ended September. The quarterly comparison shows continued growth in both metrics, alongside strong year-on-year comparisons. This differs from a comparison between the two types of margin: the available figures specify net profit margin but do not provide a comparable operating margin figure for the previous quarter.
Managing Director Sanjay Shah linked the progress to the performance of the oncology business, citing developments in regulatory approvals, technology transfer and access to global markets. Shah said the second quarter saw "tangible progress in the oncology business, with encouraging developments in regulatory approvals, technology transfer and access to global markets." The company said new approvals for oncology drugs were among the factors supporting growth, alongside demand across different geographic markets. It added that an improved oncology product mix and operating leverage contributed to performance. It also cited cost management discipline as an additional factor, broadening the explanation for the results beyond demand growth alone.
The quarterly results come as the company expands its global export model for oncology products. In a disclosure dated October 14, 2026, the company cited expansion of the export model with oncology products and the start of commercial export supplies. This places the access to global markets mentioned by the managing director within a broader development in export activity. The company is scheduled to hold a call to discuss its second-quarter and first-half financial year 2027 results on October 27, 2026, at 3:00 p.m. India time. The call will be the next opportunity for management to detail performance and the financial period following the release of unaudited results.